We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+11.88%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.92B
AUM Growth
-$2.46M
Cap. Flow
-$105M
Cap. Flow %
-2.67%
Top 10 Hldgs %
77.48%
Holding
132
New
21
Increased
29
Reduced
29
Closed
20
Avg Time Held Equity + Options
7 quarters
Top 10 Avg Time Held Equity + Options
4.2 quarters
Top 20 Avg Time Held Equity + Options
7.5 quarters
Avg Time Held Equity only
7.1 quarters
Top 10 Avg Time Held Equity only
7.2 quarters
Top 20 Avg Time Held Equity only
9.1 quarters

Top Buys

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$103M
2
CGEM icon
Cullinan Oncology
CGEM
+$22.5M
3
RNAM
Avidity Biosciences
RNAM
+$18.8M
4
VERA icon
Vera Therapeutics
VERA
+$16.3M
5
JBIO icon
Jade Biosciences
JBIO
+$15.3M

Top Sells

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$232M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$29.5M
3
VKTX icon
Viking Therapeutics
VKTX
+$20.8M
4
ALPN icon
Alpine Immune Sciences Inc
ALPN
+$16.1M
5
ONC icon
BeOne Medicines Ltd
ONC
+$15.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 56.02%
2 Healthcare 41.9%
3 Technology 0.98%
4 Miscellaneous 0.71%
5 Financials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CAVA icon
1
CAVA Group
CAVA
$6.27B
$2.18B 55.59%
23,507,990
-3,000,000
-11% -$232M
2023 Q2
4 quarters
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$748M
$294M 7.5%
175,099,384
+57,546,100
+49% +$103M
2013 Q2
44 quarters
SRRK icon
3
Scholar Rock
SRRK
$5.14B
$93.8M 2.39%
11,259,438
– –
2018 Q2
24 quarters
KYMR icon
4
Kymera Therapeutics
KYMR
$9.35B
$89.7M 2.29%
3,005,610
-21,525
-0.7% -$745K
2020 Q3
15 quarters
MORF icon
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$86.1M 2.19%
2,525,998
+312,810
+14% +$9.27M
2019 Q2
20 quarters
ARWR icon
6
Arrowhead Research
ARWR
$8.86B
$82.9M 2.11%
3,189,389
+152,721
+5% +$3.75M
2023 Q1
5 quarters
APLS icon
7
DELISTED
Apellis Pharmaceuticals
APLS
$56.3M 1.43%
1,467,080
+151,798
+12% +$6.87M
2022 Q3
7 quarters
DYN icon
8
Dyne Therapeutics
DYN
$3.11B
$53.5M 1.36%
1,516,960
-1,000
-0.1% -$29.1K
2020 Q3
15 quarters
SLN icon
9
Silence Therapeutics
SLN
$613M
$52.8M 1.35%
2,779,619
– –
2023 Q1
5 quarters
SWTX icon
10
DELISTED
SpringWorks Therapeutics
SWTX
$49.5M 1.26%
1,313,026
-102,322
-7% -$4.31M
2019 Q3
19 quarters
CRNX icon
11
DELISTED
Crinetics Pharmaceuticals
CRNX
$47.7M 1.22%
1,066,064
-324,413
-23% -$15M
2024 Q1
1 quarter
MRUS icon
12
DELISTED
Merus
MRUS
$45M 1.15%
760,355
+305,274
+67% +$14.8M
2024 Q1
1 quarter
ONC icon
13
BeOne Medicines Ltd
ONC
$40.1B
$43.3M 1.1%
303,369
-101,413
-25% -$15.6M
2016 Q4
30 quarters
RVMD icon
14
Revolution Medicines
RVMD
$40.7B
$39.4M 1.01%
1,015,776
-302,873
-23% -$11.3M
2022 Q4
6 quarters
KURA icon
15
Kura Oncology
KURA
$943M
$37.5M 0.96%
1,819,884
-100,000
-5% -$2.06M
2019 Q3
19 quarters
VERA icon
16
Vera Therapeutics
VERA
$2.15B
$33.1M 0.84%
915,974
+409,955
+81% +$16.3M
2024 Q1
1 quarter
NMRA icon
17
Neumora Therapeutics
NMRA
$89.4M
$27.8M 0.71%
2,824,052
-100,000
-3% -$1.03M
2023 Q3
3 quarters
CYTK icon
18
Cytokinetics
CYTK
$8.75B
$26.8M 0.68%
494,421
-12,163
-2% -$734K
2021 Q2
12 quarters
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$26.8M 0.68%
+655,555
New +$18.8M
2024 Q2
0 quarters
ARWR icon
20
CALL
Arrowhead Research
ARWR
$8.86B
$26M 0.66%
1,000,000
+400,000
+67% +$9.83M
2023 Q4
2 quarters
IGMS icon
21
DELISTED
IGM Biosciences
IGMS
$22.9M 0.58%
3,330,422
+250,000
+8% +$2.14M
2020 Q3
15 quarters
WVE icon
22
Wave Life Sciences
WVE
$682M
$22.8M 0.58%
4,566,251
+514,851
+13% +$2.94M
2021 Q3
11 quarters
ERAS icon
23
Erasca
ERAS
$5.61B
$22.7M 0.58%
9,630,810
+4,909,616
+104% +$10.6M
2021 Q3
11 quarters
TNGX icon
24
Tango Therapeutics
TNGX
$4.01B
$21.6M 0.55%
2,519,841
+325,000
+15% +$2.51M
2024 Q1
1 quarter
PRTA icon
25
Prothena Corp
PRTA
$454M
$20.7M 0.53%
1,001,360
– –
2023 Q4
2 quarters
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2024 Portfolio in Review

As of Q2 2024, Artal Group held 132 positions worth $3.92B, down 0.06% from $3.93B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Artal Group's Q2 2024 filing shows 21 new, 29 increased, 29 reduced and 20 closed positions. Its largest new stake was Cullinan Oncology: 1,057,949 shares worth $18.5M. The largest sale was CAVA Group, an estimated $232M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 56% of assets, up from 48% a quarter earlier, followed by Healthcare and Technology.

  • Artal Group's largest Q2 2024 buy was Cullinan Oncology: 1,057,949 shares worth $18.5M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2024, an estimated $103M increase.
  • Artal Group's biggest Q2 2024 reduction was CAVA Group, cutting an estimated $232M.
  • Artal Group fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $29.5M.
  • Artal Group's ten largest holdings make up 77% of its $3.92B portfolio in Q2 2024.
  • Artal Group opened 21 new positions and closed 20 in Q2 2024.
  • Artal Group's portfolio value fell 0.06% quarter-over-quarter to $3.92B.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.